A Phase 1/2 Study of SHP648 an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects

STATUS

Recruiting
participants needed

21
sponsor

Baxalta now part of Shire

Send

Updated on 19 February 2024

See if I qualify

gene therapy

hemophilia

viral vector

christmas disease

prophylactic

Summary

The purpose of this study is to evaluate the safety and dose escalation of SHP648 an adeno-associated viral vector for gene transfer in hemophilia B participants.

Description

This study will consists of 3 dose cohorts with 2-7 participants in each of the three ascending dose cohorts. Initially 2 participants will be dosed in Cohort 1, followed by dosing of up to 5 additional participants if the cohort is expanded. Participants in cohort 2 and 3 will receive 2-fold or 3-fold dose escalation to their respective preceding cohort doses if required.

Details

Condition	Factor IX Deficiency
Age	18years - 75years
Treatment	SHP648
Clinical Study Identifier	NCT04394286
Sponsor	Baxalta now part of Shire
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Male, aged 18 to 75 years at the time of screening
	Established severe or moderately severe hemophilia B (plasma FIX activity lesser than or equal to [<=] 2 percent (%) measured following greater than or equal to [>=] 5 half-lives of most recent exposure to exogenous FIX) and either >= 3 hemorrhages per year requiring treatment with exogenous FIX or use of prophylactic therapy
	History of greater than (>) 50 exposure days to exogenously administered FIX concentrates or cryoprecipitates
	Sexually active men must agree to use barrier contraception (combination of a condom and spermicide) or limit sexual intercourse to post-menopausal, surgically sterilized, or contraception-practicing partners for a minimum of 6 months after administration of SHP648, or until SHP648 genomes are no longer detected in the semen (whichever is sooner)
	Signed informed consent
Exclusion Criteria
	Bleeding disorder(s) other than hemophilia B
	Documented laboratory evidence of having developed inhibitors (>= 0.6 Bethesda Units [BU] on any single test) to FIX proteins at any time
	Documented prior allergic reaction to any FIX product
	Anti-AAV8 neutralizing antibody titer >= 1:5
	Known hypersensitivity to prednisolone or prednisone, or to any of the excipients
	Having a disease in which treatment with prednisolone or prednisone is not tolerated (including, but not limited to osteoporosis with vertebral fractures, severe labile hypertension, and brittle diabetes)
	Evidence of markers of potential underlying risk for autoimmune mediated hepatic
	disease
	Anti-smooth muscle antibody (ASMA) titer >= 1:40. Values of 1:31 to 1:39 will be flagged as possibly abnormal and the Investigator and Medical Monitor will evaluate the participant for eligibility
	Elevated anti-liver-kidney microsomal antibody type 1 (LKM1) titers
	Total Immunoglobulin G (IgG) > 1.5x upper limit of normal (ULN)
	Antinuclear antibody (ANA) titer > 1:320 OR ANA titer > 1:80 if demonstrated concurrently with alanine aminotransferase (ALT) that is > ULN
	Active Hepatitis C: as indicated by detectable hepatitis C virus ribonucleic acid (HCV RNA) by polymerase chain reaction (PCR)
	Hepatitis B: If surface hepatitis B virus (HBV) antigen is positive
	Receiving chronic systemic antiviral and/or interferon therapy within 4 weeks prior to enrollment
	Clinically significant infections (e.g., systemic fungal infections) requiring systemic treatment
	Known immune disorder (including myeloma and lymphoma)
	Concurrent chemotherapy or biological therapy for treatment of neoplastic disease or other disorders
	An absolute neutrophil count lesser than < 1000 cells per cubic millimetre (cells/mm^3)
	Markers of hepatic inflammation or cirrhosis as evidenced by 1 or more of the
	following
	Platelet count < 150,000/microliter (L)
	Albumin <= 3.5 gram per deciliter (g/dL)
	Total bilirubin > 1.5x ULN and direct bilirubin >= 0.5 milligram per deciliter (mg/dL)
	ALT or Aspartate aminotransferase (AST) > 1.0x ULN
	Alkaline phosphatase > 2.0x ULN
	History of liver biopsy or imaging indicating moderate or severe fibrosis (Metavir staging of F2 or greater)
	History of ascites, varices, variceal hemorrhage, or hepatic encephalopathy
	FibroSURE Score >= 0.4
	Prothrombin time international normalized ratio (INR) >= 1.4
	Serum creatinine > 1.5 mg/dL
	Human immunodeficiency virus (HIV) if cluster of differentiation 4 (CD4)+ cell count <= 200 mm^3 and/or viral load > 20 copies per milliliter (copies/mL)
	Urine protein > 30 mg/dL
	Body mass index > 38\
	Orthopedic or other major surgery planned within 6 months after enrollment
	Acute or chronic disease that, in the opinion of the Investigator, would adversely affect participant safety or compliance or interpretation of study results
	Received an AAV vector previously or any other gene transfer agent in the previous 12 months prior to Study Day 0
	Significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, congestive heart failure, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) or significant pulmonary disease (including obstructive pulmonary disease)
	History of arterial or venous thrombosis / thromboembolism, or a known pro-thrombotic condition
	Recent history of psychiatric illness or cognitive dysfunction (including drug or alcohol abuse) that, in the opinion of the Investigator, is likely to impair participants ability to comply with protocol mandated procedures
	Participation in another study involved with an investigational agent
	Participant is family member or employee of the Investigator

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

A Phase 1/2 Study of SHP648 an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects